Pyxis Oncology, Inc

Timeline

1. Oct 2, 2026 Raise Follow-on offering: $282.6M (up to, as announced), announced Oct 2, 2026. Source: company release on GlobeNewswire. source ↗
2. Sep 30, 2026 Raise Follow-on offering: $110M (total, as published), announced Sep 30, 2026. Source: company release on GlobeNewswire. source ↗
3. Jun 30, 2026 Raise Private placement: $50M (total, as published), announced Jun 30, 2026. Source: SEC filing. source ↗
4. Apr 15, 2025 Trial start 1: Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors source ↗
5. May 23, 2023 Trial start Phase 1: Study of PYX-106 in Solid Tumors source ↗
6. Mar 14, 2023 Trial start Phase 1: A Study of PYX-201 in Advanced Solid Tumors source ↗

Upcoming milestones

• Apr 25, 2027 (ESTIMATED) · Phase 1 · A Study of PYX-201 in Advanced Solid Tumors · NCT05720117
• Dec 6, 2027 (ESTIMATED) · 1 · Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors · NCT06795412

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $442.6M. Last 2 years.

• Oct 2, 2026 Follow-on offering: $282.6M (up to, as announced), announced Oct 2, 2026. Source: company release on GlobeNewswire. source ↗
• Sep 30, 2026 Follow-on offering: $110M (total, as published), announced Sep 30, 2026. Source: company release on GlobeNewswire. source ↗
• Jun 30, 2026 Private placement: $50M (total, as published), announced Jun 30, 2026. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 3